Healthcare

For the year ended 30 June 2026, Sigma Healthcare Limited (ASX:SIG) reported revenue of $10.8 billion, up 15.5% compared with normalised pro-forma FY25 figures. Normalised earnings before interest and tax (EBIT) increased 20.6% to $1,090.0 million, taking the normalised EBIT margin to 10.1%. These …

Conventional spinal cord stimulation delivers electrical pulses to influence pain-related nerve signalling. Saluda Medical (ASX:SLD) uses a feedback-based approach through its Evoke System: the device records evoked compound action potentials, or ECAPs, which are electrical responses generated by stimulation.

Syntara Limited (ASX:SNT) is a clinical-stage drug developer working on treatments for blood cancers and conditions involving inflammation and fibrosis. Its research includes compounds that inhibit lysyl oxidase enzymes, which are involved in the formation and remodelling of connective tissue. During 2026, the company …

SomnoMed Limited (ASX:SOM) develops oral appliance treatment solutions for sleep-related breathing disorders, including obstructive sleep apnoea. Its SomnoDent range uses individually fitted dental devices designed to position the jaw during sleep. In 2026, the company’s manufacturing operations and Rest Assure monitoring program remain central …

Starpharma Holdings Limited (ASX:SPL) is an Australian biotechnology company developing dendrimer-based drug delivery technologies, including its proprietary DEP platform. Its 2026 activities have included work on targeted oncology candidates, radiopharmaceuticals and funding arrangements intended to support further research and clinical development.

Telix Pharmaceuticals Limited (ASX:TLX) develops and commercialises targeted radiopharmaceuticals for cancer imaging and treatment. Its precision medicine portfolio includes prostate-specific membrane antigen (PSMA) imaging agents, alongside investigational products for kidney and brain cancers. During 2026, the company reported higher first-half revenue and advanced clinical …

Glucoprime is a beta-glucan ingredient underpinning the company’s wound-care technology. Tissue Repair Ltd (ASX:TRP) identifies TR987 as its lead investigational product for chronic wounds, including venous leg ulcers. Its approach is distinct from a conventional dressing: the company is developing formulations intended to interact …